Abstract
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists. Therefore, it is of great interest to explore novel therapeutic strategies to obtain long-term remission. Immune effector cells, and especially natural killer (NK) cells, play a crucial role in the control of hematological malignancies. In this regard, the efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated graft versus leukemia effect without the risk of inducing graft versus host disease. Alloreactive donor NK cells generated following hematopoietic stem cell transplantation ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell effector functions against resistant leukemia cells, novel immunotherapeutic strategies are oriented to the identification, isolation, expansion, and administration of particular NK cell subsets endowed with multifunctional anti-tumor potential and tropism toward tumor sites. Moreover, the relationship between the emergence and persistence of distinct NK cell subsets during post-graft reconstitution and the maintenance of a remission state is still rather unclear.
| Original language | English |
|---|---|
| Article number | 567 |
| Journal | Frontiers in Immunology |
| Volume | 6 |
| Issue number | NOV |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Keywords
- Hematological malignancies
- HSCT
- NK cell subsets
- NK cell therapy
- NK cells
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Effector functions of natural killer cell subsets in the control of hematological malignancies. / Gismondi, Angela; Stabile, Helena; Nisti, Paolo; Santoni, Angela.
In: Frontiers in Immunology, Vol. 6, No. NOV, 567, 2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effector functions of natural killer cell subsets in the control of hematological malignancies
AU - Gismondi, Angela
AU - Stabile, Helena
AU - Nisti, Paolo
AU - Santoni, Angela
PY - 2015
Y1 - 2015
N2 - Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists. Therefore, it is of great interest to explore novel therapeutic strategies to obtain long-term remission. Immune effector cells, and especially natural killer (NK) cells, play a crucial role in the control of hematological malignancies. In this regard, the efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated graft versus leukemia effect without the risk of inducing graft versus host disease. Alloreactive donor NK cells generated following hematopoietic stem cell transplantation ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell effector functions against resistant leukemia cells, novel immunotherapeutic strategies are oriented to the identification, isolation, expansion, and administration of particular NK cell subsets endowed with multifunctional anti-tumor potential and tropism toward tumor sites. Moreover, the relationship between the emergence and persistence of distinct NK cell subsets during post-graft reconstitution and the maintenance of a remission state is still rather unclear.
AB - Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists. Therefore, it is of great interest to explore novel therapeutic strategies to obtain long-term remission. Immune effector cells, and especially natural killer (NK) cells, play a crucial role in the control of hematological malignancies. In this regard, the efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated graft versus leukemia effect without the risk of inducing graft versus host disease. Alloreactive donor NK cells generated following hematopoietic stem cell transplantation ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell effector functions against resistant leukemia cells, novel immunotherapeutic strategies are oriented to the identification, isolation, expansion, and administration of particular NK cell subsets endowed with multifunctional anti-tumor potential and tropism toward tumor sites. Moreover, the relationship between the emergence and persistence of distinct NK cell subsets during post-graft reconstitution and the maintenance of a remission state is still rather unclear.
KW - Hematological malignancies
KW - HSCT
KW - NK cell subsets
KW - NK cell therapy
KW - NK cells
UR - http://www.scopus.com/inward/record.url?scp=84949678965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949678965&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2015.00567
DO - 10.3389/fimmu.2015.00567
M3 - Article
AN - SCOPUS:84949678965
VL - 6
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
IS - NOV
M1 - 567
ER -